CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
Recruiting
N/A
Interventional Study
Lynch Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 272 (estimated)
- Sponsor
- PERROD Guillaume · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers. It is characterized by a pathogenic germline mutation in one of the DNA mismatch repair genes (path\_MMR) MLH1, MSH2, MSH6, PMS2 or a deletion in the 3' region of the Epcam gene. Patients followed up for LS are at high risk of developing CRC at an early age, a…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Confirmed pathogenic mutation (path\_MLH1, path\_MSH2, path\_MSH6, path\_PMS2, path\_EpCAM)
* Male or female of legal age at time of colonoscopy prescription.
* Patient agreeing to participate in the study
* Person affiliated with or benefiting from a social security scheme
* …
Contacts